Monday, November 25, 2013
J&J's Remicade Versus Inflectra
Johnson & Johnson (JNJ-$95.63) isn’t waiting until decade’s end to expand its offering of anti-inflammatory therapies: to refresh the immunology franchise, JNJ is directing R&D at promising next-generation biologics, including the anti-interleukin (IL)-23 monoclonal antibody Guselkumab for psoriasis and rheumatoid arthritis (RA); Sirukumab, an anti-interleukin (IL)-6 monoclonal antibody in the treatment of patients with RA; and, an oral Janus Kinase (JAK) inhibitor (ASP015K) for RA.
Management also told analysts at a recent healthcare conference that new products are expected to comprise almost 46% of pharmaceutical sales by 2017. Auspicious product launches across other disease markets (including the blood thinner Xarelto, prostate cancer drug Zytiga, hepatitis-C antiviral Incivo and interleukin inhibitor Stelara for psoriasis) suggest JNJ is having early success in executing on its goal to lessen dependence on Remicade through diversification.
Read more at YCharts: J&J’s Top Drug vs. Generic: Investment Thesis
Editor David J Phillips does not hold a financial interest in any stocks mentioned in this article. The 10Q Detective has a Full Disclosure Policy.